Macquarie Group
AIMT

Macquarie Group’s Aimmune Therapeutics AIMT Stock Holding History

Macquarie Group’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,618
Closed -$56K – 2406
2020
Q3 		$56K Hold
1,618
– – ﹤0.01% 1930
2020
Q2 		$27K Buy
+1,618
New +$27.5K ﹤0.01% 2099
2018
Q3 		– Sell
-1,100
Closed -$30K – 2342
2018
Q2 		$30K Buy
+1,100
New +$33.7K ﹤0.01% 2020

Macquarie Group's AIMT Position: Q4 2020 in Review

Macquarie Group sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 1,618 shares — an estimated $56K sold.

Macquarie Group first reported a position in AIMT in Q2 2018 and held it in 3 quarters. The position peaked at $56K in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

  • Macquarie Group reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Macquarie Group sold 1,618 Aimmune Therapeutics shares in Q4 2020, an estimated $56K.
  • Macquarie Group first reported a position in Aimmune Therapeutics in Q2 2018 and held it in 3 quarters.
  • Macquarie Group's Aimmune Therapeutics position peaked at $56K in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Macquarie Group's 13F filing for Q4 2020, filed 16 Feb 2021.